By creating Posos, Emmanuel Bilbault and Benjamin Grelié are tackling the problem, which is as frequent as it is dangerous, of drug interactions which are exploding with the proliferation of treatments. The medtech has just raised 9.8 million euros.
L’drug interaction or public health issue
We speak of drug interaction when the simultaneous administration of several drugs modifies the therapeutic effects or reinforces the undesirable effects of at least one of these drugs. Despite the “contraindications”, “combinations not recommended” and other “precautions for use”, it is difficult to navigate the ocean of these drug interactions, even, it becomes a major health problem: between 2007 and 2018, Adverse drug reaction-related hospitalizations increased by 136% with one million days of hospitalization for 130,000 patients and more than 15,000 deaths per year in France At the same time, medical knowledge doubles every 73 days. Difficult, if not impossible, to follow such a rhythm.
Posos or help for caregivers in medical prescriptions
After 3 years of research and development, Emmanuel Bilbault and Benjamin Greliehave developed the first artificial intelligence capable of analyzing a prescription and formulating a treatment recommendation to help caregivers. Their research tool allows you to check the dosage and the treatment prescribed to the patient in case of doubt. For this, the Posos AI is based on more than 200 international medical sources analyzed using natural language processing.
Already used by 85,000 practitioners, medtech has just raised 9.8 million euros. Thanks to this new funding, the company, which today has 40 employees, wishes to double its workforce and accelerate its development. Two years after the creation of Posos, in 2017, the two entrepreneurs had already managed to raise 2 million to conduct a trial phase with health professionals. Today, the two entrepreneurs want to deploy Posos in hospitals and nursing homes, then with other hospital and liberal health professionals. A project that is part of the government’s roadmap, which in 2021 initiated a digital component of the Ségur de la Santé. But digitization is a long process and the needs are urgent. The sector still does not have digital tools up to its challenges.
The company sees itself as a support to doctors, allowing them to quickly identify the risks in a prescription. Help that also saves them time and lightens their mental load at a time when the hospital situation is at the heart of all concerns: lack of resources, shortage of caregivers, overwork, cyberattacks, etc.
 Study of the National College of Medical Pharmacology
 Study Peter Densen, 2011